GADAVIST

LOE Approaching

gadobutrol

NDAINTRAVENOUSSOLUTION
Approved
Mar 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
29

Mechanism of Action

Magnetic Resonance Contrast Activity

Pharmacologic Class:

Gadolinium-based Contrast Agent

Clinical Trials (5)

NCT06224543Phase 1Completed

MR Image Synthesis With Low Gadobutrol Dose and AI

Started Jun 2023
60 enrolled
Enhancing Brain Lesions
NCT05350189N/ACompleted

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Started Nov 2022
1,602 enrolled
Contrast Enhancement in Magnetic Resonance Imaging
NCT04373564Phase 4Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Started Mar 2021
2,076 enrolled
Motor FunctionCognitive FunctionContrast Media
NCT03730051Phase 4Completed

Dotarem vs Gadobutrol Contrast for Breast MRI

Started Mar 2021
300 enrolled
Breast Diseases
NCT03602339Phase 4Completed

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Started Nov 2018
157 enrolled
Magnetic Resonance Imaging